Psilocybin
March Recap: Largest Psychedelic Stocks DOWN 3.4% In March
The munKNEE Psychedelic Drug Stocks Index was DOWN 3.4% in March but is still UP 1.2% YTD and the average price targets of the above stocks represent…
TM Editors Note: This article mentions one or more penny stocks/microcaps. Such stocks are easily manipulated; do your own careful due diligence.
According to a study by Data Bridge Market Research, the global market for psychedelics is growing and will reach a value of over $6 billion within the next five years, compared to $2 billion in 2019. This represents a compound annual growth rate of over 16% for the industry.
The 7 largest psychedelic drug stocks (market caps of $75M or more) tracked in our munKNEE Psychedelic Drug Stocks index are ranked below, in descending order, as to:
- their stock performances in March and year-to-date (YTD),
- their likelihood of Financial Distress within the next 2 years according to data from macroaxis.com, and
- their average 12-month Price Targets,
- the extent of Short Interest and
- the degree of Insider Ownership (all as sourced from SeekingAlpha.com) and
- their current Market Capitalization.
- Compass Pathways (CMPS): UP 7.4% in March; UP 27.1% YTD
- 12 analysts have:
- an average year-end price target representing a 318% increase from its March 31st price and
- a consensus BUY rating,
- has a 30% Chance of Financial Distress within 2 years;
- a Short Interest of 34.0% (the number of shorted shares divided by the number of shares outstanding),
- a 42.3% Insider Ownership (directors and senior officers or other beneficial holders with 10% or more of the common shares),
- a current Market Capitalization of $371M and
- is primarily focused on the use of psilocybin* (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Read: Compass Pathways – Entering A Brave New World
- 12 analysts have:
- Incannex Healthcare (IXHL): UP 14.5% in March; DOWN 22.1% YTD
- Incannex engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies and has the largest portfolio of such products an therapies worldwide with a potential global addressable market for all Incannex’ products under development exceeds $400B per annum.
- Incannex has a current Market Capitalization of $132M.
- Incannex is a new addition to this index and is not covered by any Wall Street analysts.
- The Company is headquartered in Australia and trades on the Australian Stock Exchange (ASX) and the Nasdaq.
- Read: Incannex Healthcare Has World’s Largest Pipeline Of Psychedelic Products
- Atai (ATAI): UP 7.7% in March; DOWN 29.8% YTD
- 14 analysts have:
- an average year-end price target representing a 556% increase from its March 31st price,
- a consensus BUY rating;
- has only a 7% Chance of Financial Distress within 2 years,
- a Short Interest of 3.1%,
- only a 0.39% in Insider Ownership,
- a current Market Capitalization of $207M and
- is primarily focused on the use of ketamine*, DMT* and ibogaine*. Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
- Read: Atai Life Sciences: Long On Money; Short On Success
- 14 analysts have:
- Seelos (SEEL): DOWN 12.7%; UP 6.2% YTD
- 4 analysts have:
- an average year-end price target representing a 661% increase from its March 31st price,
- a consensus BUY rating and
- has a 61% Chance of Financial Distress within 2 years,
- a Short Interest of 5.7%,
- a 2.8% Insider Ownership,
- a current Market Capitalization of $80M and
- is primarily focused on the use of ketamine*. Go here for much more extensive information on Ketamine.
- Read: Seelos Addressing Significant And Unmet Needs In Rare Psychiatric And Movement Disorders
- 4 analysts have:
- Mind Medicine (MNMD): DOWN 14.7%; UP 48.8% YTD
- 8 analysts have:
- an average year-end price target of representing a 614% increase from the March 31st price,
- a consensus BUY rating and
- has a 54% Chance of Financial Distress within 2 years,
- a Short Interest of 8.9%,
- an 11.1% Insider Ownership,
- a current Market Capitalization of $110M and
- is primarily focused on the use of LSD* and MNMA*. Go here for much more extensive information on LSD and here for much more extensive information on MDMA.
- Read: MindMed: Researching LSD And MNMA To Treat Neurological Diseases
- 8 analysts have:
- GH Research (GHRS): DOWN 16.6% in March; DOWN 16.2% YTD
- 6 analysts have:
- an average year-end price target representing a 376% increase from the March 31st price and
- a consensus BUY rating,
- has a 58% Chance of Financial Distress within 2 years,
- a Short Interest of 7.9%,
- a 40.4% Insider Ownership,
- a current Market Capitalization of $425M and
- is primarily focused on the use of mebufotenin*, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine but is better known by its nick name, “The Toad”,
- Read: GH Resources: Focus On Treatment-Resistant Depression Paying Off
- 6 analysts have:
- Cybin (CYBN): DOWN 25.0%; UP 34.5% YTD
- 5 analysts have:
- an average year-end price target representing a 1356% increase from its March 31st price,
- a consensus BUY rating and
- has a 58% Chance of Financial Distress within 2 years,
- a Short Interest of 1.9%,
- a 21.4% Insider Ownership,
- a current Market Capitalization of $77M and
- is primarily focused on the use of DMT* and Psilocybin*. Go here for much more extensive information on DMT and here for much more extensive information on Psilocybin.
- Read: Cybin Inc. Was Down 70% In 2022 But Has Bounced Back By 59% YTD – Here’s Why
- 5 analysts have:
*Read 10 Psychedelic Substances And The 36 Companies Researching Them for a description of each of the psychedelic-based compounds mentioned in this article.
In summary:
- the munKNEE Psychedelic Drug Stocks Index:
- was DOWN 3.4% in March but is still UP 1.2% YTD
- and the average price targets of the above stocks represent an average 372% increase from their March 31st closes.
If you are interested in this category of clinical-stage psychedelic compound-based stocks consider the AdvisorShares Psychedelic ETF (PSIL) that consists of 23 such stocks but keep in mind that the vast majority have market capitalizations of $50M or less (i.e. are nano-caps). It was DOWN 11.3% in March but is still UP 1.1% YTD as compared to the munKNEE Psychedelic Drug Stocks Index featured above.
ibogaine psilocybin mdma lsd ketamine dmt n-dimethyltryptamine dimethyltryptamine psychedelic depression psychedelics stocks etf shares stock exchange nasdaq cybin mind medicine mindmed incannex healthcare compass seelos atai atai life sciences research-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness